Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Related Publications
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs Phase II Treatment Closed 18 and over NCI-W82-1276 CTEPIS-0059, W82-1276

Objectives

I.  Determine the therapeutic efficacy of 2-aminothiadiazole in patients with 
inoperable non-small cell carcinoma of the lung.
II.  Assess the toxicity of this treatment.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients aged 18 years and older with 
measurable nonresectable non-small cell carcinoma of the lung who have a life 
expectancy of at least 4 weeks and a Karnofsky performance status of at least 
30.  There may have been no chemotherapy in the 4 weeks prior to entry (6 
weeks for nitrosoureas).  Concurrent radiotherapy will be allowed, providing 
that there is at least one area of measurable disease outside the radiotherapy 
field.

Expected Enrollment

About 30 patients will be entered, at least 15 of whom will have had no 
previous chemotherapy.  Protocol closed February 1984.

Outline

Nonrandomized study.
Single-agent Chemotherapy.  2-Aminothiadiazole, ATDA, NSC-4728.

Stewart JA, Ackerly CC, Myers CF, et al.: Clinical and clinical pharmacologic studies of 2-amino-1,3,4-thiadiazole (A-TDA:NSC 4728). Cancer Chemother Pharmacol 16 (3): 287-91, 1986.[PUBMED Abstract]

Trial Contact Information

Trial Lead Organizations

Vermont Cancer Center at University of Vermont

Irwin H. Krakoff, MD, Protocol chair(Contact information may not be current)		Ph: 802-656-4414